Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 5:09 PM
Ignite Modification Date:
2025-12-24 @ 5:09 PM
NCT ID:
NCT02266550
Brief Summary:
The aims of this phase I study are to define the metabolism, excretion and pharmacokinetics of \[14C\]-BIIL 284 BS after administration of a single oral dose of 25 mg \[14C\]-BIIL 284 BS in 6 healthy volunteers. Tolerability was also assessed.
Study:
NCT02266550
Study Brief:
Protocol Section:
NCT02266550